Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4312 - Correlation of longitudinal target-lesions size with progression-free (PFS) and overall-survival (OS) in 2nd line metastatic renal cell carcinoma: a retrospective analysis of AXIS trial


09 Oct 2016


Poster display


Christophe Luhata Lungayo


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


C. Luhata Lungayo1, L. Fournier2, S. Oudard3, R.T. Elaidi4

Author affiliations

  • 1 Paris, ARTIC, 75015 Paris - Paris/FR
  • 2 Radiology, European Georges Pompidou Hospital, Paris/FR
  • 3 Medical Oncology Service, Hopital European George Pompidou, 75015 - Paris/FR
  • 4 Oncology, ARTIC, 75015 - PARIS/FR


Abstract 4312


OS and PFS are commonly correlated with response upon RECIST criteria. Whether a more dynamic approach considering overall and individual lesions trajectories may be of predictive/prognostic value is worth investigating.


Target lesions size (TL) from AXIS trial (NCT00678392: axitinib (A) vs sorafenib (S)) at baseline (bslTL) and subsequent time-points up to 24 months were retrospectively analyzed. TL were grouped by major organs. Relationship between OS/PFS and TL was assessed using mean-trajectories and joint-models (JM) with Cox/Weibull regression (C/W-R) including time to treatment interaction, with/without non-linear term. Mean trajectories obtained from unsupervised longitudinal clustering (ULC) were subject to C/W-R including S/A effect, age and IMDC risk group.


Among 713 eligible pts (A:359, S:354), overall TL trajectories of A and S did not differ for the 1st 12 months, whereas individual TL trajectories strongly varied with TL localization: largest difference between A and S were observed for bone and liver, no difference for lungs. Upon ULC, 3 clusters exhibiting different patterns were characterized, cl1: bslTL ≈ 50mm not time-varying, cl2: bslTL ≈ 150mm + decreasing rate = 5mm/month and cl3: bslTL ≈ 250mm + decreasing rate = 15mm/month. Surprisingly, cluster 3 exhibited the better PFS: HR = 0.51 (0.31-0.82) and OS: HR = 0.54 (0.29-1.02). Upon JM, PFS and OS were associated with TL trajectories, respectively p = 0.0004 and p 


Unlike overall TL, individual TL different trajectories were exhibited by A and S. Our model identified 3 clusters with different predictive and prognostic characteristics.

Clinical trial identification

Legal entity responsible for the study





All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings